Can I Stop Anticoagulation When Cancer Is in Remission?
-
- Hara Nobuhiro
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Lee Tetsumin
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nozato Toshihiro
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Terui Matsuyama Mao
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Okata Shinichiro
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nagase Masashi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Mitsui Kentaro
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nitta Giichi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Watanabe Keita
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Miyazaki Ryoichi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nagamine Sho
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Kaneko Masakazu
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nakamura Tomofumi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Nagata Yasutoshi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Miyamoto Takamichi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Obayashi Toru
- Department of Cardiology, Japanese Red Cross Musashino Hospital
-
- Ashikaga Takashi
- Department of Cardiology, Japanese Red Cross Musashino Hospital
書誌事項
- タイトル別名
-
- Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World
この論文をさがす
説明
<p>Background: The efficacy of direct oral anticoagulants (DOACs) compared with warfarin for the treatment of venous thromboembolism (VTE), and the recurrence of VTE after discontinuation of anticoagulation therapy in research are limited.</p><p>Methods and Results: This retrospective study enrolled 893 patients with acute VTE between 2011 and 2019. The cohort was divided into the transient risk, unprovoked, continued cancer treatment, and cancer remission groups. The following were compared between DOACs and warfarin: composite outcome of all-cause death, VTE recurrence, bleeding and composite outcome of VTE-related death, recurrence and bleeding. In the continued cancer treatment group, more bleeding was seen in warfarin-treated patients than in patients treated with DOACs (53.2% vs. 31.2%, [P=0.048]). In addition, composite outcome of VTE-related death and recurrence after discontinuation of anticoagulation therapy (n=369) was evaluated. The continued cancer treatment group (multivariate analysis: HR: 3.62, 95% CI: 1.84–7.12, P<0.005) and bleeding-related discontinuation of therapy (HR: 2.60, 95% CI: 1.32–5.13, P=0.006) were independent predictors of the event after discontinuation of anticoagulation therapy. VTE recurrence after discontinuation of anticoagulation therapy in the cancer remission group was 1.6% and a statistically similar occurrence was found in the transient risk group (12.4%) (P=0.754).</p><p>Conclusions: DOACs may decrease bleeding incidence in patients continuing to receive cancer treatment. In patients with bleeding-related discontinuation of anticoagulation therapy, VTE recurrence may increase. Discontinuation of anticoagulant therapy might be a treatment option in patients who have completed their cancer treatment.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 86 (6), 923-933, 2022-05-25
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390292240174785920
-
- NII論文ID
- 130008103356
- 130008116036
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 032176458
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可
